SAN DIEGO--(BUSINESS WIRE)--MBrace™ Therapeutics, Inc. (“MBrace”), a clinical-stage oncology company developing novel antibody-drug conjugates (ADCs) against solid tumor targets, today announced that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback